
|Articles|April 27, 2018
Controversies in Urologic Cancer
How can you be sure you’ve selected the best approach for your patients with urologic cancer? As our experts debate developments like MRI fusion biopsy for PCa, HIFU for low-risk prostate cancer, and white light cystoscopy, learn how you can integrate these treatments into your practice.
Advertisement
Having trouble viewing?
Once you access the file, position your mouse over the top middle for a toolbar:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5






